LGND
Ligand Pharmaceuticals
NASDAQ · Pharmaceuticals
$190.44
-1.25 (-0.65%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 179.85M | 212.86M | 1.00B | 944.72M | 909.17M |
| Net Income | -4,337,851 | -4,620,743 | 235.57M | 258.92M | 249.74M |
| EPS | — | — | — | — | — |
| Profit Margin | -2.4% | -2.3% | 23.5% | 27.4% | 27.5% |
| Rev Growth | -15.5% | -15.5% | -5.7% | +8.5% | +8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 237.14M | 257.30M | 195.72M |
| Total Equity | — | — | 1.17B | 1.39B | 1.23B |
| D/E Ratio | — | — | 0.20 | 0.19 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -31,754,489 | -35,704,538 | 340.17M | 346.84M | 320.13M |
| Free Cash Flow | — | — | 240.43M | 167.31M | 167.23M |